These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Developments in the epidemiolgy of invasive fungal infections - implications for the empiric and targeted antifungal therapy. Hof H Mycoses; 2008; 51 Suppl 1():1-6. PubMed ID: 18471155 [TBL] [Abstract][Full Text] [Related]
3. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Fera MT; La Camera E; De Sarro A Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707 [TBL] [Abstract][Full Text] [Related]
4. Fungal biofilms: From bench to bedside. Iñigo M; Del Pozo JL Rev Esp Quimioter; 2018 Sep; 31 Suppl 1(Suppl 1):35-38. PubMed ID: 30209921 [TBL] [Abstract][Full Text] [Related]
5. The changing face of fungal infections in health care settings. Fridkin SK Clin Infect Dis; 2005 Nov; 41(10):1455-60. PubMed ID: 16231257 [TBL] [Abstract][Full Text] [Related]
6. [Importance of mycoses in intra-abdominal infections]. Blinzler L; Fischer K; Just HM; Heuser D Langenbecks Arch Chir; 1997; 382(4 Suppl 1):S5-8. PubMed ID: 9333708 [TBL] [Abstract][Full Text] [Related]
7. [Strategies for antifungal treatment failure in intensive care units]. Arens C; Bernhard M; Koch C; Heininger A; Störzinger D; Hoppe-Tichy T; Hecker M; Grabein B; Weigand MA; Lichtenstern C Anaesthesist; 2015 Sep; 64(9):643-58. PubMed ID: 26349425 [TBL] [Abstract][Full Text] [Related]
9. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment. Jensen RH Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142 [TBL] [Abstract][Full Text] [Related]
11. [Nosocomial fungal infections, analysis of 149 cases]. Liu ZY; Sheng RY; Li XL; Li TS; Wang AX Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):399-402. PubMed ID: 12820917 [TBL] [Abstract][Full Text] [Related]
12. [Antifungal agents in the treatment of systemic infections: Relevance of mechanism of action, activity profile and resistances]. Cuenca-Estrella M Rev Esp Quimioter; 2010 Dec; 23(4):169-76. PubMed ID: 21191554 [TBL] [Abstract][Full Text] [Related]
13. Call to Action: How to Tackle Emerging Nosocomial Fungal Infections. Lionakis MS; Hohl TM Cell Host Microbe; 2020 Jun; 27(6):859-862. PubMed ID: 32526182 [TBL] [Abstract][Full Text] [Related]
14. Antifungal drug resistance of pathogenic fungi. Kontoyiannis DP; Lewis RE Lancet; 2002 Mar; 359(9312):1135-44. PubMed ID: 11943280 [TBL] [Abstract][Full Text] [Related]
15. Potential targets for the development of new antifungal drugs. Su H; Han L; Huang X J Antibiot (Tokyo); 2018 Nov; 71(12):978-991. PubMed ID: 30242283 [TBL] [Abstract][Full Text] [Related]
16. The global problem of antifungal resistance: prevalence, mechanisms, and management. Perlin DS; Rautemaa-Richardson R; Alastruey-Izquierdo A Lancet Infect Dis; 2017 Dec; 17(12):e383-e392. PubMed ID: 28774698 [TBL] [Abstract][Full Text] [Related]